Securities Code: 002424 Securities Abbreviation: ST BaiLing Announcement Number: 2026-027
Guizhou BaiLing Pharmaceutical Co., Ltd. Announcement on Correction of Prior Accounting Errors and Retrospective Adjustment
The Company and all members of the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Special Reminder:
- This error correction involves the consolidated and parent company financial statements for the years 2019, 2020, 2021, 2022, 2023, and 2024.
- This prior error correction results in the net profit attributable to shareholders of the listed company and the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses for 2019 and 2020 changing from positive to negative, and the company's performance for the corresponding years changing from profit to loss. It has not changed the profit or loss nature of other previously disclosed financial statements for other years. It will not have a significant impact on the company's current and subsequent financial position, operating results, and production and operation activities.
Guizhou BaiLing Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Guizhou BaiLing") held the 25th meeting of the Sixth Board of Directors on April 27, 2026, and deliberated and approved the "Proposal on Correction of Prior Accounting Errors and Retrospective Adjustment." The Company agreed to correct and retrospectively adjust the financial statements for the relevant periods in accordance with the "Accounting Standards No. 28 - Changes in Accounting Policies, Accounting Estimates and Accounting Errors" and "Rules for Information Disclosure and Reporting of Publicly Issued Securities No. 19 - Correction and Related Disclosure of Financial Information," and other relevant regulations. The details are as follows: